Tubulin/HDAC-IN-3 

Tubulin/HDAC-IN-3 (compound 12a) is a potent tubulin/HDAC dual inhibitor. Tubulin/HDAC-IN-3 effectively disrupts tubulin polymerization (IC₅₀: 5.4 μM). Tubulin/HDAC-IN-3 exhibits potent HDAC1/8 inhibitory activities, with IC₅₀ values of 0.155 and 0.177 μM, respectively. Tubulin/HDAC-IN-3 works through blocking cellular cycle, inducing apoptosis and inhibiting colony formation^[1].

Tubulin/HDAC-IN-3 (compound 12a) shows antiproliferative activity in vitro against four tumor cell lines (BE-(2)-C, A549, U87MG and HCT116), with IC₅₀ values of 0.017±0.002, 0.053±0.003, 0.056±0.005, and 0.051±0.003 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tubulin/HDAC-IN-3 (compound 12a) (25 mg/kg, intraperitoneally every three days) exhibits significant antitumor efficacy in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

552.53

C₂₈H₂₈N₂O₁₀

O=C1[C@@H](COC(C2=CC=C(C(NO)=O)C=C2)=O)[C@H](C3=CC=C(OC)C(O)=C3)N1C4=CC(OC)=C(OC)C(OC)=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tang H, et al. Discovery of chiral 1,4-diarylazetidin-2-one-based hydroxamic acid derivatives as novel tubulin polymerization inhibitors with histone deacetylase inhibitory activity. Bioorg Med Chem. 2023 Sep 7;92:117437.  [Content Brief]